The goal of whole blood immunophenotyping is to obtain quantitative (the delineation of immune cell subsets) and qualitative (activation status detection) information on immune cells. We have slightly modified the T cell immunophenotyping panel proposed by the Human Immunology Project1 to improve overall performance of our method (Table 1). Our T cell panel aims to identify naïve, central memory (CM), effector memory (EM), and effector T cells. Briefly, we discriminate doublets based on FCS-A and FCS-H. Then we gate on lymphocytes based on side scatter and CD45 levels. T cells are then identified by expression of CD3. CD3+ T cells are differentiated into γδ T cells and αβ T cells. αβ T cells are further divided into CD4+ and CD8+ T cells. CD4+ and CD8+ T cells are then analyzed for their subsets based on expression of CD45RA and CCR7: CD45RA-CCR7+ CM, CD45RA+CCR7+ Naïve, CD45RA+CCR7- effector, and CD45RA-CCR7- EM T cells1. Additionally, we also monitor their expression of activation markers such as CD38, HLA-DR, ICOS, PD-1, GITR, 4-1BB, CD69, NKG2D, and OX40 to obtain qualitative information.
To demonstrate the precision of this method, we stained peripheral whole blood samples from 4 healthy donors 5 times in one day. Figure 11 shows the relationship between percent T cell subpopulation on gated lymphocytes and percent coefficient of variance (%CV). A detailed breakdown of percent T cell subpopulations on gated lymphocytes and %CV for each subset is shown in Table 8. Data from Tests 2 and 3 are not included in Figure 11 and Table 8 for simplicity. Less than 25% CV between run (inter-assay precision) has been suggested for acceptance criteria for phenotypic biomarker assays for research use10. All measurements met this criteria except ICOS+ γδ T cells (26.64-46.39%. Table 8) and ICOS+ CD8 T cells (14.64-58.39%. Table 8). These values are shown for demonstration purposes. We do not utilize these measurements because ICOS mainly plays an important role in activation of CD4 T cells16. The trend of higher %CV in populations that comprise a low percentage for the total population was observed by others7. In case investigators are interested in monitoring rare-events, the number of cells examined needs to be increased in order to overcome greater imprecision17. Together, our data show the successful deployment of automation in the sample preparation of whole blood immunophenotyping.

Figure 1. Workflow for immunophenotyping with peripheral whole blood. Step by step workflow of immunophenotypic assay is shown. Please click here to view a larger version of this figure.

Figure 2. Overview of the method for making "Base Cocktail" and "Activation Cocktail". Steps in the method for making "Base Cocktail" and "Activation Cocktail" in the software for the automated liquid handler are shown. Please click here to view a larger version of this figure.

Figure 3. Layout for the tube rack with BACE_CT and ACT_CT. (A) shows layout for the tube rack "BACE_CT". (B) shows layout for the tube rack "ACT_CT". Please click here to view a larger version of this figure.

Figure 4. Labware definition for the tube rack with 2D barcode tubes. Step by step process of defining the tube rack with 2D barcode tubes. Please click here to view a larger version of this figure.

Figure 5. Instrument setup for the method for making "Base Cocktail" and "Activation Cocktail". It shows the deck layout for the method for making "Base Cocktail" and "Activation Cocktail". Please click here to view a larger version of this figure.

Figure 6. Setup for "Create Data Set". It shows detailed setting for "Create Data Set". Please click here to view a larger version of this figure.

Figure 7. Overview of the method for making "Master Antibody Cocktail". Steps in the method for making "Master Antibody Cocktail" in the software for the automated liquid handler is shown. Please click here to view a larger version of this figure.

Figure 8. Layout for the tube rack with 5 ml round-bottom polystyrene tubes. It shows layout for the tube rack "SPL_TUBES_1". FM3 means fluorescence minus 3 (brilliant violet 421, phycoerythrin, and allophycocyanin). Please click here to view a larger version of this figure.

Figure 9. Instrument setup for the method for making "Master Antibody Cocktail". It shows the deck layout for the method for making "Master Antibody Cocktail". Please click here to view a larger version of this figure.

Figure 10. Setup for "Transfer From File". It shows detailed setting for "Transfer From File". Please click here to view a larger version of this figure.

Figure 11. Low variability in semi-automated whole blood immunophenotyping. Single CV values of all cell populations analyzed from four healthy donors are shown as blue open circle. Regression curve is shown in the blue line. Red dotted lines indicate 95% confident bands and greed dotted lines show 95% prediction bands. Please click here to view a larger version of this figure.

Figure 12. An example of suboptimal staining. Staining was conducted with adequate or inadequate vortexing of microfuge tubes from "BACE_CT" and "ACT_CT". There are two gated populations in B. The minor population with weak CD45 staining represents cells that do not get optimal staining. Please click here to view a larger version of this figure.
| GROUP | MARKER | FLUOROPHORE | Clone | TITER (µl/staining) |
| BASE COCKTAIL | TCELL | CD45 | FITC | 2D1 | 0.4 |
| CD3 | Alexa700 | UCHT1 | 1 |
| CD8 | APC-H7 | SK1 | 0.4 |
| CD4 | PerCP-CY5.5 | SK3 | 2 |
| CCR7 | PE-CF594 | 150503 | 1 |
| CD45RA | PE-Cy7 | L48 | 1 |
| TCRab | BV786 | T10B9.1A-31 | 1 |
| TCRgd | BV650 | B1 | 5 |
| ACTIVATION COCKTAIL-1 | TEST1 | HLA-DR | BV421 | G46-6 | 5 |
| CD278(ICOS) | PE | DX29 | 5 |
| CD38 | APC | HB7 | 1 |
| ACTIVATION COCKTAIL-2 | TEST2 | CD279(PD1) | BV421 | EH12.1 | 2.5 |
| CD357(GITR) | PE | eBioAITR | 5 |
| CD137(41BB) | APC | 4B4-1 | 10 |
| ACTIVATION COCKTAIL-3 | TEST3 | CD69 | BV421 | FN50 | 1 |
| CD314(NKG2D) | PE | 1D11 | 2 |
| CD134(OX40) | APC | ACT35 | 5 |
Table 1. An antibody list for the modified T cell panel.
| AB | BC |
| CD45_FITC | 0163562388 |
| CD3_Alexa700 | 0163562110 |
| CD4_PerCP_CY5.5 | 0163562364 |
| CD8_APC-H7 | 0163562363 |
| CCR7_PE-CF594 | 0163562387 |
| CD45RA_PE-Cy7 | 0163562091 |
| TCRab_BV786 | 0163562069 |
| TCRgd_BV650 | 0163562108 |
| A_HLA-DR_BV421 | 0163562339 |
| A_CD278(ICOS)_PE | 0163562082 |
| A_CD38_APC | 0163562317 |
| A_CD279(PD1)_BV421 | 0163562340 |
| A_CD357(GITR)_PE | 0163562093 |
| A_CD137(41BB)_APC | 0163562315 |
| A_CD69_BV421 | 0163562341 |
| A_CD314(NKG2D)_PE | 0163562314 |
| A_CD134(OX40)_APC | 0163562316 |
Table 2. Antibody names with 2D barcode numbers.
| GROUP | WELL_BASE | AB_NAME | VOL |
| TCELL | 1 | CD8_APC-H7 | 7.2 |
| TCELL | 1 | CD45_FITC | 7.2 |
| TCELL | 1 | CD3_Alexa700 | 18 |
| TCELL | 1 | CCR7_PE-CF594 | 18 |
| TCELL | 1 | CD45RA_PE-Cy7 | 18 |
| TCELL | 1 | TCRab_BV786 | 18 |
Table 3. A file "BASE_CT_P50": antibody names and volume information.
| GROUP | WELL_BASE | AB_NAME | VOL |
| TCELL | 1 | CD4_PerCP_CY5.5 | 36 |
| TCELL | 1 | TCRgd_BV650 | 90 |
Table 4. A file "BASE_CT_P200": antibody names and volume information.
| GROUP | WELL_ACT | AB_NAME | VOL |
| TEST1 | 7 | A_HLA-DR_BV421 | 30 |
| TEST1 | 7 | A_CD278(ICOS)_PE | 30 |
| TEST1 | 7 | A_CD38_APC | 6 |
| TEST2 | 13 | A_CD279(PD1)_BV421 | 15 |
| TEST2 | 13 | A_CD357(GITR)_PE | 30 |
| TEST3 | 19 | A_CD314(NKG2D)_PE | 12 |
| TEST3 | 19 | A_CD69_BV421 | 6 |
| TEST3 | 19 | A_CD134(OX40)_APC | 30 |
Table 5. A file "ACT_ CT_P50": antibody names and volume information.
| GROUP | WELL_ACT | AB_NAME | VOL |
| TEST2 | 13 | A_CD137(41BB)_APC | 60 |
Table 6. A file "ACT_CT _P200": antibody names and volume information.
| DONOR# | SRC_
BASE | BASE COCKTAIL | WELL_
BASE | VOL_
BASE | SRC_ACT | ACTI-
VATION
COCKTAIL | WELL_
ACT | VOL_ACT | DEST_MACT | WELL_
MACT |
| HD001 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | FM3 | 1 | 25 | SPL_TUBES_1 | 1 |
| HD001 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST1 | 7 | 36 | SPL_TUBES_1 | 7 |
| HD001 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST2 | 13 | 42.5 | SPL_TUBES_1 | 13 |
| HD001 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST3 | 19 | 33 | SPL_TUBES_1 | 19 |
| HD002 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | FM3 | 1 | 25 | SPL_TUBES_1 | 2 |
| HD002 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST1 | 7 | 36 | SPL_TUBES_1 | 8 |
| HD002 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST2 | 13 | 42.5 | SPL_TUBES_1 | 14 |
| HD002 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST3 | 19 | 33 | SPL_TUBES_1 | 20 |
| HD003 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | FM3 | 1 | 25 | SPL_TUBES_1 | 3 |
| HD003 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST1 | 7 | 36 | SPL_TUBES_1 | 9 |
| HD003 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST2 | 13 | 42.5 | SPL_TUBES_1 | 15 |
| HD003 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST3 | 19 | 33 | SPL_TUBES_1 | 21 |
| HD004 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | FM3 | 1 | 25 | SPL_TUBES_1 | 4 |
| HD004 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST1 | 7 | 36 | SPL_TUBES_1 | 10 |
| HD004 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST2 | 13 | 42.5 | SPL_TUBES_1 | 16 |
| HD004 | BASE_CT | TCELL | 1 | 36.8 | ACT_CT | TEST3 | 19 | 33 | SPL_TUBES_1 | 22 |
Table 7. A file "AB_MACT":Source and destination information for "Master Antibody Cocktail".
| Population # in Fig. 1 | i | ii | iii | iv | v |
| Population name | CD3+ | ab T cells | gd T cells | CD3+CD4+ | CD3+CD8+ |
| % of lymphocytes | Heathly donor #1 | 79.80 | 75.20 | 2.70 | 49.60 | 22.30 |
| Heathly donor #2 | 69.40 | 61.90 | 5.85 | 44.40 | 16.20 |
| Heathly donor #3 | 75.80 | 69.60 | 4.75 | 42.00 | 23.50 |
| Heathly donor #4 | 77.20 | 73.50 | 1.98 | 52.70 | 18.90 |
| %CV | Heathly donor #1 | 1.42 | 1.58 | 3.70 | 2.50 | 1.56 |
| Heathly donor #2 | 2.48 | 2.39 | 5.74 | 2.82 | 2.41 |
| Heathly donor #3 | 1.15 | 1.40 | 6.32 | 1.42 | 2.72 |
| Heathly donor #4 | 0.81 | 0.94 | 5.45 | 1.20 | 1.44 |
| Average | 1.47 | 1.58 | 5.30 | 1.99 | 2.03 |
| Standard deviation | 0.72 | 0.61 | 1.13 | 0.79 | 0.63 |
Table 8. Raw data for % of lymphocytes and % CV for each subset plotted in Figure 4. Note that data for Tests 2 and 3 are not shown in Figure 5 and Table 8 to simplify data presentation.